Centurium Capital
VC Fund
Beijing, China
Centurium Capital is a VC fund in Beijing focused on Software and Biotechnology. Centurium Capital, founded by former head of Warburg Pincus Asia, is a leading Greater China focused private equity firm.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 63%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Centurium Capital invests in
Stages Centurium Capital invests in
Countries Centurium Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Software 5 (16%)
- Biotechnology 5 (16%)
- Health Care 4 (13%)
- Pharmaceutical 4 (13%)
- Logistics 3 (9%)
Stage
- Series C 9 (28%)
- Series D 5 (16%)
- Series A 4 (13%)
- Series B 4 (13%)
- Private Equity 4 (13%)
Country
- China 23 (72%)
- Israel 1 (3%)
- Hong Kong 1 (3%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Chen
Partner and Managing Director
|
Partner and Managing Director | Total investments: 1 | Find email | |
Yunze Chen
Vice President
|
Vice President | Total investments: 0 | Find email | |
Zhixing Chen
Director
|
Director | Total investments: 2 | Find email | |
David Li
Founder, Chairman & Chief Executive Officer
|
Founder, Chairman & Chief Executive Officer | Total investments: 2 | Find email | |
Mingxia Li
Chief Communications Officer
|
Chief Communications Officer | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Excalipoint Therapetics
|
Excalipoint Therapeutics is a Private limited company. | $27.7M / Seed / Mar 18, 2026 | |
LASO Biotech
|
Genebox is a leading consumer genetics company. | Series B / Nov 26, 2025 | |
Innogen Pharmaceutical
|
Innogen Pharmaceutical Technology is a high-tech, innovation-driven international pharmaceutical manufacturing, and R&D company. | Private Equity / Jan 01, 2024 | |
MitrAssist
|
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valveto work in unison with it and to enhance valve functionality.MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development. | $100M / Series C / Sep 26, 2023 | |
Yogo Robot
|
Yogo Robot is a robotics company dedicated to developing automated delivery solutions. Yogo Robot offers an open, extensive, and versatile multi-robot ecological system that consists of smart delivery stations, robotic couriers, and Internet of Things devices. The system boosts efficiency in last-mile delivery and provides a more seamless userexperience than ever before. Yogo Robot is transforming how goods are transported and reimagining how humans and robots will coexist in the future by enabling the delivery industry with cutting-edge robotic technology at the terminal end. | Series C / Oct 21, 2022 | |
NTX™
|
NTX™ is committed to creating revolutionary textile solutions through continuous research and innovation that are ecologically and economically sustainable. | $200M / Series C / Jul 31, 2022 | |
Da Yu Deng Yu Jiu
|
Da Yu Deng Yu Jiu is a light-stroke bubble wine brand that manufactures and produces low-level wine drinks for the public. | $15.7M / Series A / Apr 13, 2022 | |
seyond
|
The goal of Seyond is to develop, construct, and manufacture in large quantities the most advanced LiDAR systems with the best performance in the globe. | Private Equity / Jan 01, 2022 | |
Reading Technology
|
Reading Technology is an R&D company that uses imaging, data, AI diagnosis, and treatment technology for heart and brain diseases. | Series A / Nov 26, 2021 | |
Meican
|
Meican.com (美餐) is a platform and website focused on providing mobile ordering of foods, detailed take-out menus as well as personal and enterprise meal ordering services. It enables users choose meals by themselves from many cooperative restaurants and enjoy personalized delicacy. Meican.com also enables enterprises become efficient in terms ofdelivering orders as well as solving the problems of food classification and settlement so that they can focus on their core business.Meican.com has vast experience of product research and development and offline operation due to its professional team. Established in Jan. 2011, Meican.com covers four major cities like Beijing, Shanghai, Guangzhou and Shenzhen, and it owns more than 30,000 cooperative restaurants. | $100M / Series E / Nov 11, 2021 | |
| See all 32 investments → | |||
Co-Investors
Joy Capital
3 deals together
6 Dimensions Capital
2 deals together
CITIC Capital Holdings
2 deals together
GIC
2 deals together
HSG
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Centurium Capital invest in?
Centurium Capital invests primarily in Software, Biotechnology and Health Care startups, most often at Series C and Series D stage. Most of the 32 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Centurium Capital?
Public channels for Centurium Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Centurium Capital?
The team at Centurium Capital includes Michael Chen (Partner and Managing Director), Yunze Chen (Vice President) and Zhixing Chen (Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
